Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.About:
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.read more
Citations
More filters
Journal ArticleDOI
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
TL;DR: The association of antihypertensive drugs with incident diabetes is therefore lowest for ARB and ACE inhibitors followed by CCB and placebo, beta blockers and diuretics in rank order.
Journal ArticleDOI
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Diabetes Uk,Heart Uk +1 more
TL;DR: The Joint British Societies’ guidelines (JBS 2) on cardiovascular disease prevention in clinical practice were developed by a Working Party with nominated representatives from six professional societies to promote a consistent multidisciplinary approach to the management of people with established atherosclerotic cardiovascular disease (CVD) and those at high risk of developing symptomatic atherosclerosis.
Journal ArticleDOI
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Satoshi Umemura,Hisatomi Arima,Shuji Arima,Kei Asayama,Yasuaki Dohi,Yoshitaka Hirooka,Takeshi Horio,Satoshi Hoshide,Shunya Ikeda,Toshihiko Ishimitsu,Masaaki Ito,Sadayoshi Ito,Yoshio Iwashima,Hisashi Kai,Kei Kamide,Yoshihiko Kanno,Naoki Kashihara,Yuhei Kawano,Toru Kikuchi,Kazuo Kitamura,Takanari Kitazono,Katsuhiko Kohara,Masataka Kudo,Hiroo Kumagai,Kiyoshi Matsumura,Hideo Matsuura,Katsuyuki Miura,Masashi Mukoyama,Satoko Nakamura,Takayoshi Ohkubo,Yusuke Ohya,Takafumi Okura,Hiromi Rakugi,Shigeyuki Saitoh,Hirotaka Shibata,Tatsuo Shimosawa,Hiromichi Suzuki,Shori Takahashi,Kouichi Tamura,Hirofumi Tomiyama,Takuya Tsuchihashi,Shinichiro Ueda,Yoshinari Uehara,Hidenori Urata,Nobuhito Hirawa +44 more
TL;DR: The story of the life and times of Toshihiko Umemura and his family in the years leading up to and including his death.
Journal ArticleDOI
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Valentin Fuster,Lars Rydén,Davis S. Cannom,Harry J.G.M. Crijns,Anne B. Curtis,Kenneth A. Ellenbogen,Jonathan L. Halperin,G. Neal Kay,Jean-Yves Le Huezey,James E. Lowe,S. Bertil Olsson,Eric N. Prystowsky,Juan Tamargo,L. Samuel Wann +13 more
TL;DR: Developed in partnership with the Heart Rhythm Society L.A. Ellenbogen, MD, FACC, FHRS, and Michael D. Ezekowitz, MB, ChB, F ACC.
Journal ArticleDOI
Printed educational materials: effects on professional practice and healthcare outcomes
Anik Giguère,Jeremy M. Grimshaw,Stéphane Turcotte,Michelle Fiander,Agnes Grudniewicz,Sun Makosso-Kallyth,Fredric M. Wolf,Anna Farmer,Marie-Pierre Gagnon +8 more
TL;DR: The results of this review suggest that when used alone and compared to no intervention, PEMs may have a small beneficial effect on professional practice outcomes.
References
More filters
Journal ArticleDOI
Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Lennart Hansson,Lars H Lindholm,Leo Niskanen,Jan Lanke,Thomas Hedner,Anders Niklason,Kimmo Luomanmäki,Björn Dahlöf,Ulf de Faire,Claes Mörlin,Bengt E. Karlberg,P. O. Wester,Jan-Erik Björck +12 more
TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI
An updated coronary risk profile. A statement for health professionals.
TL;DR: Using a simple worksheet, a patient's 5- and 10-year CHD risks can be estimated using components of the profile selected because they are objective and strongly and independently related to CHD.
Journal ArticleDOI
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
TL;DR: Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
Related Papers (5)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg,Jackson T. Wright,Barry R. Davis,Jeffrey A. Cutler,Michael H. Alderman,Henry R. Black,William C. Cushman,Richard H. Grimm,L. Julian Haywood,Frans H. H. Leenen,Suzanne Oparil,Jeffrey L. Probstfield,Paul K. Whelton,Chuke Nwachuku,David Gordon,Michael A. Proschan,Paula Einhom,Charles E. Ford,Linda B. Piller,I. Kay Dunn,David C. Goff,Sara L. Pressel,Judy Bettencourt,Barbara DeLeon,Lara M. Simpson,Joe Blanton,Therese S. Geraci,Sandra M. Walsh,Christine Nelson,Mahboob Rahman,Anne Juratovac,Robert Pospisil,Lillian Carroll,Sheila Sullivan,Jeanne Russo,Gail Barone,Rudy Christian,Sharon Feldman,Tracy Lucente,David A. Calhoun,Kim Jenkins,Peggy McDowell,Janice Johnson,Connie Kingry,Juan Alzate,Karen L. Margolis,Leslie Ann Holland-Klemme,Brenda Jaeger,Jeff D. Williamson,Gail T. Louis,Pamela Ragusa,Angela Williard,R. L Sue Ferguson,Joanna Tanner,John H. Eckfeldt,Richard S. Crow,John Pelosi +56 more